The Redwood Blog

E-E-A-T in the Age of AI Search: How Life Sciences Companies Build the Authority That Gets Them Cited

Wed, 24 Jun 2026 18:36:26 GMT

The Next Shift in AI Is Already Here

There's a question that didn't exist three years ago but now sits at the center of every serious digital marketing strategy: when a buyer asks an AI tool to recommend vendors, explain a technology, or compare solutions in your category, why would your company be cited rather than a competitor?

The answer, increasingly, comes down to a framework that Google developed for evaluating content quality and that AI systems have quietly adopted as a proxy for source credibility: E-E-A-T. Experience, Expertise, Authoritativeness, and Trust.

For life sciences companies, E-E-A-T isn't just an SEO consideration. It's the foundation of visibility in an era where AI systems are assembling the vendor shortlists, writing the category summaries, and shaping buyer perceptions before a sales conversation ever begins. Getting it right is no longer optional. It's the price of being in the room.

What E-E-A-T Actually Is

Google introduced the concept of E-A-T (Expertise, Authoritativeness, Trust) in its Search Quality Evaluator Guidelines as a framework for assessing whether content deserved to rank well. In 2022, it added a fourth dimension: Experience. The addition was significant because it shifted the framework from purely credential-based authority to something more grounded in demonstrated, first-hand knowledge.

Each dimension means something specific.

Experience refers to direct, first-hand engagement with the subject matter. A medical device company writing about surgical workflow optimization demonstrates experience when its content reflects the actual clinical environments, procedural nuances, and implementation realities that only come from working directly in that space. Content written at a distance from the subject, even technically accurate content, scores lower on this dimension than content that clearly reflects lived expertise.

Expertise refers to the depth of knowledge on a subject. In life sciences, this typically means scientific and technical depth: understanding the underlying mechanisms, the methodological tradeoffs, the validation requirements, and the edge cases that a non-expert would miss. Expertise is signaled through the specificity and accuracy of the content, the credentials of the authors, and the degree to which the content adds something beyond what's already widely available.

Authoritativeness refers to recognition by others in the relevant field. It's the external validation dimension of the framework: being cited by credible sources, referenced in industry publications, mentioned by recognized experts, and having a documented track record of contributing to the knowledge base of your category. Authority isn't self-declared. It's conferred by the broader ecosystem.

Trust is the dimension Google considers most foundational. It encompasses the accuracy and honesty of your content, the transparency of your organization, the security and reliability of your website, and the consistency between what you claim and what third parties say about you. In regulated industries, trust signals also include compliance with relevant standards, clear authorship attribution, and the absence of content that makes unsupported claims.

Why Life Sciences Companies Face a Higher Bar

Google applies E-E-A-T standards unevenly across the web, and for good reason. A low-quality blog post about travel destinations is a minor inconvenience. A low-quality piece of content about laboratory protocols, clinical outcomes, or medical device performance can influence decisions with real consequences.

This is why Google classifies health, medical, scientific, and financial content as YMYL — Your Money or Your Life. Content in YMYL categories is held to a significantly higher E-E-A-T standard than content in lower-stakes categories. For life sciences companies, this means the bar for being considered a credible, citable source is materially higher than it is for most B2B industries.

The practical implication is that content strategies that work for software companies or professional services firms may not meet the standard required for life sciences visibility in AI search. Generic thought leadership, lightly sourced claims, and content written without clear author attribution may be adequate for less scrutinized categories. In life sciences, they're not.

The opportunity this creates is real. Most competitors face the same elevated standard and most aren't meeting it. Building genuine E-E-A-T authority in a YMYL category is harder than in a low-stakes one, but the competitive advantage it creates is also more durable. Once established, authority in a regulated, technically demanding field is difficult for competitors to replicate quickly.

How AI Systems Use E-E-A-T Signals

The connection between E-E-A-T and AI citation authority is not officially documented by Google or other AI providers. But the evidence from observing which sources get cited in AI-generated answers is consistent: the sources that appear most frequently are those that would score well on E-E-A-T criteria.

This makes intuitive sense. AI systems are trained on the web's existing content and learn to weight sources the way credible human researchers do: favoring sources that are specific, well-attributed, externally validated, and accurate. When an AI synthesizes an answer about lab automation platforms, it doesn't randomly select which companies to mention. It surfaces the ones whose digital presence signals credibility — consistent content, credible authors, third-party mentions, and technical depth that demonstrates genuine expertise.

The practical implication is that building E-E-A-T authority serves two goals simultaneously. It improves your visibility in traditional Google search, where E-E-A-T signals have always mattered. And it builds the kind of source credibility that makes AI systems more likely to cite you when buyers are asking the questions that shape their vendor shortlists.

These are no longer separate strategies. They're the same strategy.

Building E-E-A-T Authority in Life Sciences: What It Actually Requires

Understanding the framework is straightforward. Building the authority it describes is a sustained organizational commitment. Here's what it requires in practice for a life sciences company.

Author credibility and attribution. Content published anonymously or under a generic company byline scores poorly on the expertise and experience dimensions. AI systems and search algorithms both look for signals that real, credible humans with relevant credentials are behind the content. This means attributing content to named authors with documented credentials, building author bio pages that establish scientific or technical background, and where possible, featuring content from recognized subject matter experts, scientific advisors, or KOLs who lend their authority to your content program.

Technical depth and specificity. Shallow content that restates category-level information signals low expertise. Content that adds genuine analytical value, original perspective, or specific technical detail that isn't widely available elsewhere signals high expertise. For life sciences companies, this means moving beyond product-centric content toward genuinely educational material: detailed protocol guides, methodology comparisons, validation frameworks, application-specific use cases, and analysis of emerging research relevant to your category.

Structured, navigable content architecture. Trust signals include the organization and clarity of your content, not just its substance. Well-structured pages with clear headings, logical organization, appropriate schema markup, and clean technical foundations signal to both search algorithms and AI systems that your content is produced by a credible organization that takes its digital presence seriously. Conversely, poorly organized websites with broken links, outdated content, and missing metadata undermine trust signals regardless of how good the underlying content is.

Third-party citation and earned mentions. Authoritativeness is the dimension that's hardest to build unilaterally because it requires external validation. The most effective approaches for life sciences companies include contributing to industry publications, presenting at recognized conferences, participating in peer-reviewed content where appropriate, securing mentions in analyst reports, and building relationships with industry voices who reference your work. Each external mention is a signal that the broader community of knowledge recognizes your authority in your category.

Consistent publishing and content freshness. Trust signals include evidence that your organization is actively maintaining its content and staying current with developments in your field. A blog last updated eighteen months ago, product pages with outdated specifications, and resources that reference superseded standards all undermine trust signals. A consistent publishing cadence, regular content reviews, and timely updates when relevant developments occur in your category all build the trust dimension over time.

Transparent organizational information. Google's trust signals include basic organizational transparency: a clear About page, identifiable leadership, documented contact information, and consistency between what you claim and what third parties say about you. For life sciences companies operating in regulated environments, this also means consistency between your marketing claims and your regulatory filings, published standards compliance, and any relevant certifications or quality designations your organization holds.

The AI Citation Audit

A practical starting point for any life sciences company serious about building E-E-A-T authority is what might be called an AI citation audit. The exercise is straightforward but often revelatory.

Open ChatGPT, Perplexity, Claude, and Gemini. Ask each one the questions your target buyers are most likely to ask: "What are the leading platforms for lab automation in drug discovery?" "How do I evaluate CRO partners for early-phase oncology studies?" "What should I look for in a flow cytometry system for clinical applications?" Note which companies get cited, which claims get attributed to which sources, and whether your organization appears at all.

If you're not appearing, the audit gives you a clear picture of what you're competing against. Look at the sources that are being cited. What do they have that your digital presence doesn't? In most cases, the answer comes back to E-E-A-T signals: more specific content, clearer author attribution, more third-party mentions, stronger technical depth. The gap between where you are and where you need to be is your E-E-A-T roadmap.

The Long Game

E-E-A-T authority isn't built in a quarter. It's built through sustained investment in content quality, author credibility, and external recognition over time. That timeline is both the challenge and the competitive moat.

Companies that start building genuine E-E-A-T authority now will be significantly harder to displace in AI search results in two or three years than companies that treat content as a volume exercise and authority as something that happens automatically. The barriers to entry are not technical. They're organizational: the discipline to invest in depth over breadth, the commitment to author attribution and scientific credibility, and the patience to build the third-party recognition that authoritativeness requires.

In life sciences, where the science is the product and credibility is the currency, those are investments that compound.

Up next: How life sciences companies build the kind of digital authority that gets them cited by AI search tools — and why the bar is higher in regulated industries than almost anywhere else.

I work with life sciences companies on digital marketing strategy, from SEO/AEO and content to demand generation, positioning and messaging, omnichannel campaigns, product launches, voice of customer, and more. If this resonated, or if you have a different perspective, I'd genuinely like to hear from you.

Why Most Life Sciences Companies Are Positioned to Sound Exactly Like Their Competitors

Mon, 08 Jun 2026 21:05:49 GMT

The Sameness Problem

Here's a test worth running right now. Go to your website, remove your logo, and read your homepage as if you've never heard of your company. Then do the same for your three closest competitors.

If the pages are interchangeable — and in most cases they will be — you have a positioning problem. Not a writing problem, not a design problem. A positioning problem. And it's one of the most commercially costly issues a life sciences company can have, because when buyers can't differentiate between vendors, decisions slow down, sales cycles lengthen, and price becomes the deciding factor.

This is happening across the industry right now, and it's not for lack of capability. Most life sciences companies have genuinely differentiated products, real scientific innovation, and meaningful results to point to. The problem is that their positioning doesn't reflect any of it.

The Category Trap

The most common positioning failure in life sciences has a name: the category trap. It works like this.

A company defines its market category — lab equipment, CRO services, genomics platforms, medical device — and then builds its positioning around the attributes that define that category. Speed. Scalability. Accuracy. Flexibility. Global reach. Scientific expertise. These are the things every company in the category claims, because they're the baseline requirements for competing in it at all.

The result is positioning that is technically accurate and completely undifferentiated. Every vendor in the category is faster, smarter, more scalable, and more flexible than the alternative. Every one of them has deep scientific expertise and a global footprint. None of those claims give a buyer a reason to choose one over another.

The category trap is seductive because it feels safe. Claiming what the category claims means you're unlikely to say anything wrong. But in positioning, safety is the enemy of differentiation. The companies that win aren't the ones that describe the category most accurately. They're the ones that stake out a specific, defensible position within it — or adjacent to it — that competitors can't easily replicate.

Why This Keeps Happening

Understanding the category trap is one thing. Understanding why smart companies keep falling into it is another.

In my experience, the most common cause is an over-reliance on internal perspective. Positioning developed by looking inward at what the company believes makes it great, what the founding team is proud of, what the product roadmap prioritizes, produces positioning that resonates internally and lands flat externally. What your organization values about itself is rarely what your buyers value about you.

Competitive benchmarking compounds the problem. Many companies build their positioning by studying competitors and trying to match or exceed their claims. The logical outcome of this approach is convergence: everyone ends up saying approximately the same things because everyone is reacting to everyone else. Positioning built through comparison produces positioning that sounds like the category, not like a company with a specific, defensible point of view.

The third cause is the absence of difficult choices. Strong positioning requires saying no. It requires choosing a specific audience, a specific problem, and a specific way of solving it — and accepting that this choice means some buyers won't immediately see themselves in your story. Most organizations find that degree of specificity uncomfortable, particularly when leadership is concerned about leaving revenue on the table. The result is positioning that tries to speak to everyone and resonates with no one.

What Differentiated Positioning Actually Requires

Real differentiation in life sciences positioning starts with one question that most companies haven't answered rigorously: why do customers actually choose you, as opposed to why do you think they choose you?

These are different questions, and the answers are almost always different. The features your product team is most proud of are frequently not the factors that drove a buyer's decision. The capabilities your marketing team emphasizes

are often not the ones that came up in the sales conversation that closed the deal. The positioning you've built around your technology may be less important to buyers than the way your team shows up during implementation.

The only way to find out is to ask. Win/loss interviews, voice of customer research, and structured conversations with existing customers about their decision process will surface the real reasons people choose you. Those reasons — specific, buyer-validated, and grounded in actual purchase decisions — are the raw material of differentiated positioning.

What you're looking for is the intersection of three things: what you do genuinely better than alternatives, what buyers actually care about at the moments that matter most in their evaluation, and what competitors cannot credibly claim. That intersection is your positioning territory. Everything outside it is either undifferentiated or unsustainable.

The Messaging Architecture That Brings Positioning to Life

Positioning is a strategic choice. Messaging is how that choice gets expressed across every buyer-facing surface. The gap between the two is where most life sciences companies lose the thread.

A positioning statement — however well-crafted — doesn't drive content, sales conversations, or campaign copy on its own. What's needed is a messaging architecture: a structured framework that translates the positioning into specific messages for specific audiences at specific stages of their evaluation.

In practice, this means defining the core value proposition that applies across your full audience, then layering persona-specific messages that address the specific concerns of each buying committee member. The scientific evaluator needs a different expression of your positioning than the economic buyer, who needs a different expression than the procurement stakeholder. The underlying positioning is consistent. The way it's communicated adapts to who's listening and what they care about.

This is why positioning and messaging work done in isolation from the buying committee (built for a single, generic customer) produces materials that resonate with nobody in particular. A messaging architecture built around a real buying committee, grounded in real buyer intelligence, produces content that moves specific people forward at specific moments in their evaluation.

The AI Dimension

There's a new urgency to getting positioning right that didn't exist a few years ago. Multiple research sources now confirm that AI tools have fundamentally changed how B2B buyers discover and evaluate vendors. A March 2026 analysis of 680 million AI citations found that 73% of B2B buyers now use AI tools like ChatGPT and Perplexity in their research process. Forrester's 2025 survey of more than 4,000 buyers found that 61% of the buying journey completes before the buyer contacts a vendor — a figure that rises further when AI tools are providing synthesized competitive comparisons.* In practical terms, this means a buyer may have already formed a view of your positioning, your competitors, and your relative strengths before anyone on your team knows they exist.

This changes the stakes of positioning in a specific way. When a buyer asks an AI tool to compare vendors in your category, the AI synthesizes an answer from whatever is publicly available about each company: website content, third-party mentions, published materials, industry coverage. If your positioning is generic and your messaging sounds like the category, that's what gets synthesized. If your positioning is specific, credible, and consistently expressed across your digital presence, that's what gets surfaced.

In the answer engine era, your positioning isn't just what you say to buyers directly. It's what AI systems learn to say about you when buyers aren't talking to you at all. Generic positioning that blends into the category doesn't just fail in sales conversations — it fails to register in the AI-mediated discovery process that increasingly precedes those conversations.

A Practical Starting Point

Repositioning a life sciences brand is not a small undertaking. But getting started doesn't require a full strategic overhaul. A few focused moves will tell you quickly whether your current positioning is working and where the gaps are.

Run the homepage test described at the start of this post, but do it systematically. Pull the homepages of your five closest competitors and yours. Strip the logos. Read them as a buyer would. Note every phrase that appears on more than two pages; those are typically category claims, not differentiators. What's left, if anything, is your actual positioning territory.

Talk to three customers who chose you over a competitor in the last twelve months. Ask them specifically what tipped the decision. Not what they valued about your product generally, but what made them choose you at the moment of decision. The answers will likely surprise you and will almost certainly point to something more specific than what your current positioning emphasizes.

Ask your sales team which messages land and which ones don't. Which claims generate follow-up questions and engagement? Which ones get a polite nod and no response? Sales conversations are the most honest real-time test of whether positioning is resonating, and most marketing teams don't tap that intelligence systematically.

Then make a choice. Pick the most specific, defensible, buyer-validated position you can occupy and build your messaging architecture around it. Resist the temptation to hedge with qualifiers and additional claims that dilute the specificity. The goal is a position that some buyers will find immediately compelling and others won't immediately recognize themselves in. That's not a failure of positioning. That's how positioning is supposed to work.

The Commercial Case

Positioning isn't a branding exercise. It's a commercial lever, and the commercial consequences of weak positioning are real and measurable.

When buyers can't differentiate between vendors, they slow down. They add more evaluation steps, bring in more stakeholders, and extend the sales cycle trying to find a basis for decision. When they still can't differentiate, they default to price. Deals that should close on value close on discount, and margins compress accordingly.

Strong positioning does the opposite. It gives buyers a clear, credible reason to prefer you before the sales conversation begins. It shortens the evaluation process because the differentiation is already established. It reduces price sensitivity because buyers who understand specifically why you're the right choice are less likely to treat the decision as a commodity.

In a market where most companies sound like their competitors, clear and specific positioning is one of the few remaining sources of durable competitive advantage. It's also one of the most underinvested.

*Sources

Loganix. 2026 B2B AI Buying Behavior Analysis. April 3, 2026. Based on a multi-source synthesis of six independently published studies conducted between October 2025 and March 2026, covering 680 million AI citations, 2,961 controlled research sessions, and 1.96 million browsing sessions across ChatGPT, Perplexity, Gemini, and Google AI Overviews. https://www.prnewswire.com/news-releases/73-of-b2b-buyers-use-ai-tools-in-purchase-research-multi-source-analysis-finds-302733319.html

Forrester Research. B2B Buyer Survey. 2025. Survey of 4,000+ business buyers examining the B2B buying journey and vendor contact behavior.

The Content Strategy Gap, Part 3: What a Sophisticated Persona-Based Content Strategy Actually Looks Like

Tue, 02 Jun 2026 19:28:28 GMT

This is Part 3 of a three-part series on building a content strategy that actually works in life sciences B2B. Part 1 examined why these strategies fail before they start. Part 2 explored why the buying committee gets lopsided content coverage. This post shows what it looks like when it's built right.

From Diagnosis to Solution

The first two posts in this series diagnosed the problem. Persona-based content strategies fail because they're treated as projects rather than systems, and because the buying committee rarely gets equal content coverage. The technical evaluator is well served. Everyone else — the economic buyer, procurement, IT, the executive sponsor — is largely left to fend for themselves, with predictable consequences for pipeline and deal velocity.

This post is about what the solution actually looks like in practice. Not as a theoretical framework, but as a working model that a life sciences company can build, sustain, and compound over time. It requires more organizational discipline than most teams expect. The pipeline outcomes it produces justify that investment many times over

Start With Real Buyer Intelligence, Not Assumptions

Every content strategy is only as good as its understanding of the buyer. And most content strategies are built on assumptions — internal beliefs about what buyers care about, what questions they ask, and what content influences their decisions — rather than on what buyers have actually said.

The starting point for a sophisticated content strategy is voice of customer research: structured conversations with recent buyers, recently lost prospects, and existing customers about their actual buying experience. Not about your product, but about their process. What triggered the evaluation? What questions did they have at each stage? Where did they look for information, and increasingly, what did they ask AI tools like ChatGPT or Perplexity, and did your brand appear in those answers? What content did they encounter that was useful? What would have made their evaluation easier or faster? What almost derailed the deal?

The answers are almost always surprising and almost always specific. A lab automation buyer might tell you that the piece of content that most influenced their decision was a third-party validation study they found through a peer recommendation, not anything on your website. A procurement stakeholder might tell you that they spent three weeks trying to find your vendor compliance documentation and almost pulled you from consideration because they couldn't. An economic buyer might tell you that nobody ever gave them a clear answer to the total cost of ownership question, and they had to piece it together from multiple conversations and documents.

This intelligence, gathered directly from the people who have lived the buying journey, is what separates a content strategy built on insight from one built on assumption. It also produces immediate, actionable content briefs: every gap a buyer names is a content opportunity.

Supplement VOC interviews with what's already available internally. Sales call recordings, win/loss analysis, CRM notes from closed and lost deals — these are rich sources of buyer intelligence that most marketing teams don't systematically mine. A few hours reviewing recent call recordings with a specific focus on the questions buyers asked and the concerns they raised will surface more actionable content direction than most formal persona workshops.

Build the Messaging Matrix

Once the buyer intelligence is assembled, the next step is organizing it into a structure that drives content creation systematically. The tool for this is a messaging matrix.

A messaging matrix is a framework that maps specific messages to specific personas at specific buying stages. Think of it as a grid: buying stages run across the horizontal axis (awareness, consideration, evaluation, decision, post-purchase), and buying committee personas run down the vertical axis (technical evaluator, economic buyer, procurement, IT stakeholder, executive sponsor). Each cell in the grid represents the intersection of one persona and one buying stage.

For each cell, the messaging matrix captures four things: the primary question this persona is asking at this stage, the key message that addresses it, the proof point that makes that message credible, and the content format that delivers it most effectively to this persona at this stage.

The power of the messaging matrix is that it makes content gaps visible in a way that a content calendar or a topic list never can. When you look at the grid and see that the economic buyer row is almost entirely empty at the consideration and evaluation stages, you know exactly where to invest next. When you see that the procurement row has no content at any stage, you know why deals are stalling. The matrix translates buyer intelligence into editorial direction.

It also creates alignment. When sales, marketing leadership, and the content team all share the same messaging matrix, there's a common framework for prioritizing content investment, evaluating new content ideas, and measuring whether the content library is actually serving the buying committee. Decisions that used to be subjective become answerable by reference to the matrix.

An Illustrative Example

To make this concrete, consider a composite scenario drawn from the kinds of engagements common in life sciences B2B: a mid-size lab automation company targeting pharmaceutical and biotech accounts with 500 to 5,000 employees, an average deal size of $150,000 to $500,000, and a typical sales cycle of nine to twelve months.

Their messaging matrix reveals two significant gaps that VOC research has confirmed are actively costing them deals.

The first gap is at the intersection of the economic buyer persona and the evaluation stage. At this point in the buying process, the economic buyer is asking: "What is the actual cost of this investment when I account for implementation, training, maintenance, and integration, and what return can I realistically expect?" The company has no content that answers this question. Sales has been answering it verbally, inconsistently, in individual conversations. The content solution is a structured total cost of ownership framework with a simplified calculator, accompanied by a one-page business case template that the technical champion can adapt and present to their budget authority internally.

The second gap is at the intersection of the procurement persona and the consideration stage. Procurement is asking: "Is this vendor someone we can work with? Do they meet our supplier requirements, and can I get everything I need to put them through our vendor qualification process without it becoming a project?" The company has no vendor qualification documentation, no supplier compliance overview, and no content that speaks to procurement's specific concerns. The content solution is a vendor qualification package: a supplier overview document, a standard terms summary, a quality and compliance overview, and a FAQ that anticipates the most common procurement questions.

Building these two content assets doesn't require a large content investment. It requires understanding specifically what each persona needs and producing content in the format and language they'll actually use.

Add the Omnichannel Layer

Content that exists but doesn't reach the right persona through the right channel at the right time is content that doesn't work. The messaging matrix defines what to create. The omnichannel layer defines how to distribute it, and as covered in an earlier post in this series, the goal isn't channel presence. It's channel coherence.

Different buying committee members are reachable through different channels, and the distribution strategy has to reflect that reality. LinkedIn thought leadership reaches technical evaluators and executive sponsors who are actively engaged in professional content consumption. Email nurture sequences reach contacts already in your funnel, where you can deliver persona-specific content based on what you know about their role and their stage. Paid content syndication through channels like TechTarget reaches procurement and IT stakeholders who are researching vendor categories but don't follow your LinkedIn page. SEO and AEO-optimized content, built to rank in traditional search and to be cited by AI answer engines like ChatGPT, Perplexity, and Claude, reaches buyers across all personas during the extended independent research phase, before they've engaged with anyone on your team.

Account-level orchestration adds another dimension. Using intent data and marketing automation, you can track engagement across multiple contacts at the same account and coordinate timing so that different buying committee members receive relevant content in a sequence that mirrors the internal conversation they're likely having. When your analytics show that a technical evaluator at a target account has downloaded a technical guide and an economic buyer at the same account has started visiting your pricing page, that's a signal to coordinate outreach across both contacts rather than treating them as independent leads.

Tradeshows and live events integrate into this model as relationship-building accelerants. Events like SLAS or AACR concentrate relevant buying committee members in a single location, creating relationship opportunities that digital channels can't replicate. But events work best when they're embedded in an omnichannel sequence: pre-event outreach that warms target accounts before the show, at-show engagement that deepens relationships established digitally, and post-event follow-up that continues the conversation with persona-specific content rather than a generic "great to meet you" email.

Build the Organizational Infrastructure

The content and the distribution strategy are only sustainable if the organizational infrastructure exists to support them. This is where most initiatives eventually break down, as discussed in Part 1 of this series, and it's worth being direct about what's required.

Editorial governance means a content calendar that maps every planned piece to a specific persona, a specific buying stage, a specific channel, and a specific business objective. Not just a topic and a publish date. If a proposed piece of content can't be placed in a cell of the messaging matrix, it shouldn't be on the calendar.

Sales and marketing alignment requires a regular cadence, monthly at minimum, where sales shares what they're hearing in buyer conversations and marketing shares what content is being consumed and by whom. This meeting is the primary mechanism for keeping the messaging matrix current and ensuring that content investment is tracking with actual buyer behavior rather than historical assumptions.

Performance measurement should track content engagement by persona and buying stage, not just aggregate traffic and downloads. Which personas are engaging with which content? Which buying stages are well-trafficked and which are showing gaps? Which content assets are being used by sales in conversations, and which are sitting untouched in the library? These questions should drive a quarterly review of the content strategy, including updates to the messaging matrix when new intelligence warrants it.

Someone needs to own this system. Not just individual content pieces, but the framework itself: the persona assumptions, the messaging matrix, the editorial governance process, the sales and marketing alignment cadence, and the performance review cycle. Without a designated owner, the system degrades as competing priorities accumulate, exactly the sustainability failure pattern described in Part 1 .

Where to Start When You Can't Build Everything at Once

For marketing teams without the resources to build the full model immediately, the answer isn't to wait until the resources exist. It's to prioritize and build systematically.

Start with the highest-value gap, not the easiest one. Review your recent lost deals and identify the persona whose unmet content needs most consistently appear in the post-mortem. If procurement is the recurring friction point, start there. If economic buyers are consistently unable to make the business case internally, start there. Building one well-researched, well-targeted content asset for an underserved persona delivers more pipeline value than five generic pieces that don't address a specific need.

Phase the build over a realistic timeline. A twelve-month content roadmap for a resource-constrained team might address two underserved personas in the first quarter, add a third in the second, and begin building out weaker buying stages in the second half of the year. Progress compounds: each new asset fills a specific gap, and the library becomes more complete with every editorial cycle.

The minimum viable content strategy for a lean team includes a partially populated messaging matrix, one new content asset per underserved persona per quarter, a monthly thirty-minute sales and marketing alignment conversation, and a quarterly review of what's working. This is enough to start building a system, and a system, even a small one maintained consistently, will outperform a large initiative that launches strongly and then collapses under its own weight.

What Success Looks Like

When a persona-based content strategy is functioning as it should, the evidence shows up in the sales process before it shows up in the analytics.

Sales has content for every buying committee conversation, not just the technical ones. When a procurement stakeholder raises a vendor qualification question, the sales rep has something to send. When an economic buyer asks for a business case framework, it exists. When an executive sponsor needs a two-page strategic narrative to present to their leadership team, marketing has already produced it.

The handoff from marketing to sales comes with context. This account has engaged with these specific assets. These personas are active. Based on their content consumption, here is where they appear to be in their evaluation. That context makes the first sales conversation more productive and shortens the time it takes to establish credibility.

Deals move faster because buyers encounter relevant, credible content at every stage of their evaluation rather than hitting gaps that force them to pause, ask questions, or look elsewhere. The content strategy stops being a source of friction and starts being a source of competitive advantage.

Over time, the content library compounds. Each new piece fills a specific gap in the messaging matrix. The library becomes more complete, the buying committee becomes better served, and the competitive advantage widens with every editorial cycle. That compounding effect is the real return on a content strategy built as a system rather than a project.

The Underlying Point

A sophisticated persona-based content strategy isn't a deliverable. It's an operating model. The messaging matrix, the omnichannel distribution layer, the organizational infrastructure, and the feedback loop aren't separate initiatives. They're components of a single system that only works when all the parts are functioning together.

The companies that build it correctly don't just produce better content. They create a sustained competitive advantage in a market where the buying process is long, the buying committee is complex, and trust is the deciding factor in most competitive situations.

The investment is real. The discipline required is significant. And for teams that can't build everything at once, the answer is to start with the highest-value gap and build from there. A system built slowly and maintained consistently will always outperform a project launched boldly and abandoned quietly.

The Content Strategy Gap, Part 2: Are All Personas Treated Equally?

Mon, 18 May 2026 15:36:23 GMT

This is Part 2 of a three-part series on building a content strategy that actually works in life sciences B2B. Part 1 examined why persona-based strategies fail before they start. Part 3 will show what a fully realized content strategy looks like in practice.

The Persona Coverage Problem

If you audit the content library of most life sciences companies against their stated personas, a pattern emerges almost every time. The technical persona (the scientist, the researcher, the lab director) is well served. There are blog posts, application notes, webinars, and white papers written squarely for that audience. Most other cohorts are an afterthought.

Procurement gets a compliance checklist, if they're lucky. Finance gets a datasheet that was written for the technical evaluator and doesn't speak to their concerns at all. The C-suite gets a one-pager that nobody reads. The IT stakeholder gets nothing, until they raise an integration concern late in the deal and suddenly everyone is scrambling to put something together. This isn't random. It's the predictable result of a marketing team creating content for the audience they're most comfortable writing for, not necessarily the audience most influential in getting a deal closed.

Mapping the Life Sciences Buying Committee

Before examining why content coverage becomes lopsided, it helps to be explicit about who is typically involved in a complex life sciences purchase and what each stakeholder actually needs. The technical evaluator (scientist, researcher, lab director, application specialist) is the most visible stakeholder early in the buying process. They drive the initial evaluation, define the technical requirements, and typically champion a preferred solution internally. Their content needs are well understood: depth, specificity, scientific credibility, and technical proof points.

The economic buyer (CFO, VP of Operations, or whoever controls the budget) enters the conversation later but carries significant decision authority. Their questions are different: what is the total cost of ownership, what is the expected return on this investment, how does this compare to the alternatives, and what happens if this doesn't deliver. They are rarely served by the application notes and scientific webinars that dominate most life sciences content libraries.

The procurement stakeholder cares about vendor compliance, contract terms, approved vendor lists, and risk. They're not evaluating your science — they're evaluating your company as a vendor. Do you meet their supplier requirements? What does your warranty and service model look like? How have other organizations similar to theirs managed the procurement process for this type of purchase? This content almost never exists in any meaningful form.

The IT or informatics stakeholder is concerned with integration, data security, system compatibility, and implementation requirements. In an era when lab automation and informatics platforms are increasingly interconnected, and when AI-powered tools are being embedded into laboratory workflows, this stakeholder is becoming more influential in purchase decisions and more likely to be an unexpected source of deal friction when their concerns aren't proactively addressed.

The executive sponsor or champion is typically a C-suite or senior leadership contact who needs to approve the investment and, in some cases, advocate for it internally. They need a compelling strategic narrative: how does this purchase connect to the organization's priorities, what is the organizational risk of doing nothing, and why is now the right time. A twelve-page white paper is not the right way to reach this stakeholder.

Why the Technical Persona Dominates Content Investment

The concentration of content investment around the technical evaluator isn't irrational — it reflects several real dynamics that are worth understanding before trying to correct them. Marketing teams in life sciences are often folks' who have scientific backgrounds or strong science-adjacent expertise. They write well for technical audiences because they understand those audiences deeply. Writing for a CFO or a procurement manager requires a different set of knowledge and a different vocabulary, and it's harder for a team whose expertise is in the science.

The technical persona is also the most visible early in the buying process. They're the ones downloading white papers, attending webinars, and engaging with content in ways that show up in marketing analytics. The economic buyer, the procurement stakeholder, and the executive sponsor are largely invisible until they enter the conversation through sales, which means marketing rarely gives or gets direct feedback about what content those personas actually need.

Established content formats in life sciences — application notes, scientific posters, technical webinars, peer-reviewed publications — are built for scientific audiences. They're the formats the industry recognizes as credible, and they're the formats marketing teams are most practiced at producing. Creating an ROI calculator for a CFO or a vendor risk assessment guide for a procurement team requires building new content capabilities, not just applying existing ones to a new topic.

Finally, there's a widespread assumption, often unstated and rarely examined, that winning the scientist is sufficient to close the deal. If the scientist champions your solution strongly enough, the thinking goes, the economic buyer and procurement team will fall in line. This assumption is wrong often enough to matter, and when it's wrong, the consequences are significant. Early in my career, I would work tirelessly with Product Marketing and Application Scientists spending 80-90% of my time developing messaging and content for the primary i nfluencers ( the lab director and research scientists), but a disproportionately small amount of time on key decision makers: procurement, C-suite, VP of Clinical Development, and others. Results were less than stellar and the sales organization quickly made it clear that they needed more support toward the end of the buying journey when key decision makers were brought into the evaluation.

The Real Cost of Lopsided Content Coverage

When the buying committee doesn't have content that addresses their specific concerns, the gap gets filled, but rarely in ways that help the deal.

When deals stall at procurement, it's often because nobody has proactively addressed vendor compliance requirements. The procurement team raises questions that sales isn't prepared to answer in writing, a back-and-forth begins that can take weeks, and in the meantime competitive alternatives that look more procurement-ready gain ground.

Economic buyers enter late in the cycle with no content foundation and ask fundamental questions. What's the ROI? What's the total cost of ownership? How does this compare to the build-versus-buy alternative? Questions that should have been answered in content months earlier, were addressed ad hoc in sales conversations, with less consistency and less credibility than a well-constructed written asset would provide.

IT stakeholders raise integration concerns that nobody anticipated addressing in the content strategy. These concerns are legitimate and often deal-critical, but because no content exists to address them proactively, they become obstacles rather than solved problems. Executive sponsors have no compelling narrative to take to their board or leadership team. The technical champion is enthusiastic, but the person who needs to approve the budget can't articulate the strategic case for the investment because nobody gave them the language to do it. Internally, the deal loses momentum.

Sales is left to create ad hoc materials for every underserved persona: custom one-pagers, modified presentations, email responses that piece together answers from whatever existing content they can find. These materials are inconsistent, off-brand, and time-consuming to produce. They also represent a significant opportunity cost: the time sales spends creating content as opposed to selling.

What Equal (and Strategic) Persona Coverage Actually Looks Like

The goal isn't to produce the same volume of content for every persona. It's to ensure that every member of the buying committee has what they need to advance their evaluation and make a confident decision. That means mapping content explicitly to each buying committee member at each stage of the journey. The technical evaluator might need ten pieces of content across the buying cycle. The economic buyer might need three. But those three pieces need to be as carefully researched, as specifically targeted, and as well-executed as the ten.

Format is as important as topic. A C-suite executive brief should be two pages, written in business language, focused on strategic outcomes and organizational risk. A procurement vendor assessment guide should anticipate the specific questions a procurement team will ask and answer them in a format that travels easily through an internal review process. An IT integration overview should speak the language of systems architecture, not scientific workflows. Producing the right content for the wrong format, or the right format for the wrong content, still fails the persona.

The ROI and business case content that economic buyers need is often the hardest to produce because it requires close collaboration between marketing and finance (and sometimes the customer themselves, e.g. case studies and testimonials), and because it demands an accounting of value that not all organizations are comfortable putting in writing. It's also frequently the most influential content in a buying cycle. A well-constructed ROI framework that a technical champion can hand to a CFO is often the difference between a deal that closes and one that stalls indefinitely.

A Diagnostic Exercise

Before building new content, it's worth understanding specifically where your current coverage breaks down. Conduct a post-mortem with your content team (including Product Marketing, Sales, Scientists) and evaluate where content was critical in facilitating - or hindering - the sale. Determine what needs to improve, what's still missing, and what was particularly effective. Pull your last five lost deals and map where buying committee engagement broke down. Was it a procurement hold? An economic buyer who couldn't make the business case internally? An IT concern that surfaced too late? The pattern across those five deals will tell you more about your content gaps than any internal audit.

Audit your existing content library against each persona and each buying stage. Create a simple grid — personas on one axis, buying stages on the other — and place each significant content asset in the appropriate cell. The empty cells are your content strategy. Ask sales directly: which stakeholder conversations are hardest to support with existing content? Which questions do they consistently have to answer from scratch because nothing in the content library addresses them? Sales will tell you immediately, and the answers are usually specific enough to generate content briefs fairly quickly.

The Underlying Point

A content strategy that serves the technical evaluator well but leaves the economic buyer, procurement stakeholder, IT contact, and executive sponsor without adequate support isn't a full content strategy. It's a scientific communication program with a strategy label on it. Winning consistently in life sciences B2B requires content that moves every member of the buying committee forward, at every stage of their evaluation, in the format they'll actually use. That's a higher bar than most organizations are currently meeting, and it's exactly the bar that separates the companies with predictable pipeline from the ones wondering why good technical evaluations keep stalling before they close.

Part 3 of this series shows what it looks like when the full content strategy is built deliberately: the messaging matrix, the omnichannel orchestration, the organizational requirements, and where to start when you can't build everything at once.

The Content Strategy Gap, Part 1: Why Persona Based Content Strategy Fails Before It Starts

Wed, 13 May 2026 19:26:20 GMT

Part 1 of a three-part series on building a content strategy that actually works in life sciences B2B.

When Good Strategy Goes Nowhere

There's a moment most life sciences marketing leaders recognize, even if they don't talk about it openly. It usually comes about six months after a persona and buyer journey initiative wraps up. Someone pulls up the deliverables (the persona profiles, the journey maps, the messaging framework, etc.) and realizes that none of it is actually driving content decisions. The calendar looks almost identical to what it did before the initiative began. The personas are on a slide deck. The journey map is pinned to a conference room wall. The strategy that generated genuine excitement at kickoff has quietly become shelf ware.

This isn't a failure of the framework. Personas and buyer journey maps are genuinely useful tools when they're built and used correctly. The failure is almost always in execution; and the reasons behind it are more structural than most organizations acknowledge.

The Persona Development Problem

The way most organizations build personas sets them up to fail before the first piece of content is written. Personas are typically developed in a workshop setting, by a marketing team working largely from internal assumptions, and then documented in a format that looks comprehensive but is functionally too vague to drive content decisions. "Senior Lab Manager, 40-55, values efficiency and reliability, influences purchasing decisions" is a demographic description, not a content brief. It tells you who the person is in broad strokes. It tells you almost nothing about what to write for them.

What's missing from most persona development processes is the psychological layer: the specific questions this person is asking at each stage of their evaluation, the objections they raise when they encounter your category, the information gaps that cause them to stall or disengage, and the proof points that actually move them forward. That information doesn't come from internal workshops. It comes from talking to buyers; something most persona development processes treat as optional rather than foundational.

The second problem is isolation. Personas are almost always built by marketing without meaningful input from sales. This is a significant gap, because sales talks to buyers every day. They hear the questions, the objections, the competitive comparisons, and the concerns that never make it into a formal RFP. A persona built without that intelligence is a persona built on assumption, and each of us marketers understands that assumption-based content often produces content that misses.

The Buyer Journey Map Problem

Buyer journey maps suffer from a related but distinct set of problems. The most common issue is that they reflect how marketing believes buyers behave rather than how buyers actually behave. In life sciences, the buying journey is rarely the clean, linear progression from awareness to consideration to decision that journey maps typically depict. Buyers loop back. They restart evaluations when a stakeholder changes. They spend months in independent research mode before anyone on your team knows they exist. They consult peers and communities that your analytics will never capture.

Most journey maps also stop too early. They document the path to the hand-raise, e.g. the moment a prospect fills out a form or requests a conversation, without adequately accounting for the extended pre-awareness research phase that determines which vendors even make the consideration set. In life sciences, that pre-awareness phase can last months. If your content strategy doesn't serve buyers during that period, you may never get the opportunity to serve them at all.

The third problem is stasis. Journey maps are built, presented, approved, and then rarely updated. The market moves, buyer behavior shifts, new channels emerge — including AI-powered search tools that are fundamentally changing how buyers find and evaluate vendors — and the journey map stays exactly as it was on the day it was completed. A static map driving a dynamic content strategy is a map that becomes less useful with every passing quarter.

Why Life Sciences Amplifies Every One of These Problems

The structural challenges of persona-based content strategy exist in most B2B industries. In life sciences, they're more acute. Sales cycles in biotech, medtech, and lab automation frequently run six to eighteen months. That means the content strategy has to account for sustained, independent buyer research over an extended period , and not just a few touchpoints before a sales conversation. A journey map that doesn't reflect this reality will consistently misallocate content investment toward the wrong stages.

The buying committee in life sciences is also more complex than in most industries. A single capital equipment or software purchase might involve a principal investigator, a lab director, a procurement team, an IT stakeholder, and a C-suite approver, each with different questions, different information sources, and a different definition of a successful outcome. Building one or two personas and calling the buying committee covered is a shortcut that shows up as lost deals.

Technical audiences add another layer. Scientists and researchers expect a level of content depth and specificity that generic persona frameworks don't anticipate. A drug developer isn't moved by vague promises of 'streamlined workflows.' They want to understand how your system integrates with their existing liquid handling platform, what the throughput implications are for their specific assay format, and what the validation requirements look like for a GMP environment. Producing that content requires more than a persona profile. It requires genuine subject matter expertise and a content development process that can support it.

The Organizational Failure Underneath the Tactical Failure

Behind the persona development and journey mapping problems is a more fundamental organizational failure: the absence of the systems and structures needed to make a content strategy function as an ongoing discipline rather than a one-time initiative. The most common symptom is the missing feedback loop. In nearly all of the organizations I've worked for or consulted with, most have no formal mechanism for connecting content performance data back to persona assumptions. If a white paper written for the economic buyer is getting almost no engagement, that's a signal. It's either an irrelevant topic, the format is wrong, the channel is wrong, or the persona assumption underlying the content is wrong. Without a process for asking and answering that question, the same mistakes get repeated in the next content cycle.

Sales and marketing misalignment compounds this. The content marketing is often disconnected from the questions sales is actually hearing in the field. Sales reps build their own ad hoc materials to fill the gaps (one-pagers, slide decks, even brochures) that are inconsistent, off-brand, off-message, and invisible to the marketing team. The result is two parallel content ecosystems that never inform each other.

Volume pressure is the final organizational trap. When content teams are measured on output, e.g. posts published, assets produced, campaigns launched, the path of least resistance is content that's easy to create, not content that's strategically targeted. Checking the persona box by adding a generic "for lab managers" tag to a piece of content is not the same as creating content that serves a lab manager's specific needs at a specific buying stage. In an environment that rewards volume, the distinction gets lost.

The Sustainability Problem: Why Programs That Launch Well Still Fail

Perhaps the most underappreciated failure mode in persona-based content strategy is this: the program launches successfully, generates real momentum, produces genuine deliverables, and then quietly degrades over the following twelve to eighteen months until it exists in name only.

This pattern is so common in large marketing organizations that it has almost become accepted as inevitable. It isn't inevitable, but understanding why it happens is a prerequisite for preventing it.

Leadership changes are the single most disruptive factor. A new CMO or VP of Marketing arrives with their own strategic priorities, their own preferred frameworks, and their own mandate to put their stamp on the function. The existing persona and content strategy — regardless of its quality — gets questioned, restructured, or quietly set aside in favor of whatever the new leader wants to build. Months or years of accumulated institutional knowledge about buyers, messaging, and content performance can be lost in a single leadership transition.

The discipline required to sustain the program is consistently underestimated at launch. Running a functioning persona-based content strategy requires ongoing editorial governance, regular cross-functional alignment between sales and marketing, and a level of process rigor that competes with every other priority on a busy marketing team's plate. In the first few months, when the initiative is new and energy is high, that rigor is relatively easy to maintain. As the novelty fades and other priorities accumulate, it becomes progressively more difficult to sustain.

Training and retraining is a continuous investment that most organizations treat as a one-time event. As team members turn over, institutional knowledge about the personas, the messaging architecture, and the editorial rationale leaves with them. New team members need to be onboarded into the framework, which takes time and leadership attention that is rarely budgeted for. Without it, new hires default to their own instincts and prior habits, and the framework erodes from within.

Updating the strategy when new learnings emerge requires both a process and a culture that most organizations haven't built. What sales is learning in the field, what content performance data is revealing, what win/loss analysis is surfacing is that all of this should be flowing back into the persona and journey map assumptions on a regular basis. In most organizations I've worked for, it doesn't. The strategy calcifies while the market moves, and the gap between the documented framework and the actual buyer reality widens with every quarter it goes unaddressed.

The compounding effect of these factors is what produces the shelf ware outcome. Each factor is manageable in isolation. When leadership changes coincide with team turnover, competing priorities, and an absent feedback loop, the program doesn't just stagnate, it actively deteriorates, often without anyone explicitly deciding to abandon it.

The Underlying Point

Persona-based content strategy is not a project. It's an operating model. The difference between organizations that make it work and those that produce expensive shelf ware isn't the quality of the initial deliverables, it's whether the organization has built the systems, disciplines, and leadership commitment to sustain the framework over time.

That's a harder problem than building a good persona profile. It's also the problem worth solving because the compounding value of a well-maintained content strategy is one of the most durable competitive advantages available to a life sciences marketing organization. Part 2 of this series will examine a specific and underappreciated symptom of these failures: not all personas are treated equally, and the ones that get the least content attention are often the most influential in closing a deal.

From Fragmented to Unified: Building an Omnichannel Strategy for Complex B2B Buying Committees

Tue, 21 Apr 2026 21:08:46 GMT

From Fragmented to Unified: Building an Omnichannel Strategy for Complex B2B Buying Committees

There's a conversation that happens in a lot of life sciences marketing teams, usually triggered by a lost deal or a pipeline review that doesn't add up. Someone asks: "How did they find us?" And the answer is almost always more complicated than anyone expected. They read a blog post six months ago. They saw you at a conference. Someone on their team got an email. Their scientist looked you up after a webinar. Their procurement lead ran a Google search. Nobody talked to sales until month four.

This is the reality of modern B2B buying in life sciences — and it's the reason omnichannel strategy matters as much as it does. The challenge in 2026 isn't deciding where to show up. It's making every touchpoint feel like part of the same coherent conversation, whether a buyer encountered you on LinkedIn last Tuesday or at a tradeshow six months ago.

The Buying Committee Problem

Before getting into tactics, it helps to name the specific challenge that makes omnichannel strategy genuinely hard in life sciences. You're rarely selling to one person. Capital equipment purchases might involve a principal investigator or lab director who evaluates technical and clinical fit, a procurement team focused on price and vendor compliance, an IT or informatics stakeholder who cares about integration and data security, and a C-suite or finance lead who signs off on budget. Each of these people has different questions, different information sources, and different definitions of a good vendor.

Generally, they don't coordinate their research with each other. They're consuming content independently, at different points in the buying cycle, through different channels. And they're forming opinions about your company long before anyone on your team knows they exist. An omnichannel strategy for this environment isn't about broadcasting the same message everywhere. It's about understanding who is likely to show up on which channel, what they need to see when they get there, and how to make those separate encounters feel like a continuous, coherent brand experience.

What "Omnichannel" Actually Means (And What It Doesn't)

The word gets misused enough that it's worth being direct about the distinction. Multichannel marketing means being present on multiple channels. You have a website, a LinkedIn page, an email program, and you exhibit at conferences. Each channel operates independently. The email team (I’m using “team” loosely; often this is one person) doesn't know what happened at the tradeshow. The website doesn't reflect what sales is saying in conversations. The LinkedIn content has nothing to do with the nurture sequence someone is getting in their inbox.

Omnichannel marketing means those channels are coordinated. The story a buyer hears on LinkedIn connects to the content they find on your website, which connects to the follow-up they receive after downloading a white paper, which connects to the conversation a sales rep has with them three months later. Every touchpoint knows, in some sense, what the others have been saying. The gap between these two states is where most life sciences companies currently live. They're multichannel by presence and siloed by execution. Fixing that gap is the actual work of your omnichannel strategy.

The Channels That Matter Most in Life Sciences B2B

Not every channel deserves equal investment, and life sciences buying behavior is specific enough to make some clear prioritization possible.

LinkedIn is the primary digital channel for professional discovery and brand building in this space. Decision-makers, scientists, and procurement leads all have a LinkedIn presence, and it's where thought leadership content gets the most traction. For companies targeting a defined set of accounts, LinkedIn's targeting capabilities — by job title, company, industry, seniority — are genuinely valuable, and they're not dependent on third-party cookies. Organic content from company leadership builds familiarity over time; paid campaigns can accelerate awareness with specific personas at specific accounts. Side note: LinkedIn is primarily a brand-building channel in this context, not a lead generation engine — the platform's value lies in creating familiarity and credibility with the right audiences over time, not in driving direct conversions from a single post or campaign.

Email remains one of the highest-ROI channels in B2B when it's done well. This means segmented, relevant, and paced for a long buying cycle. A scientist interested in mass spectrometry, and a procurement lead evaluating vendor compliance should not be receiving the same email sequence nor messaging. The ability to tailor content to the role and buying stage is what separates email programs that generate pipeline from email programs that generate unsubscribes.

Content, SEO, and AEO function as the always-on layer of your omnichannel strategy. When a buyer is in independent research mode (which, in life sciences, is most of the time), they're searching for answers through both traditional search engines and increasingly through AI-powered answer engines like ChatGPT, Perplexity, and Claude. Being present at those moments — whether as a ranked result in Google or as a cited source in an AI-generated answer — requires genuinely useful, technically credible content that is structured for both human readers and AI retrieval. Blog posts, white papers, application notes, and FAQs all serve this function, and when built with both SEO and AEO in mind, they extend your brand's reach across every channel where independent buyer research is happening.

Tradeshows and events remain disproportionately important in life sciences relative to other industries. The concentration of relevant buyers at events like the American Academy of Clinical Research (AACR), Society of Toxicology (SoT), or the Radiological Society of North America (RSNA) creates relationship-building opportunities that digital channels can't fully replicate. But events work best as part of an omnichannel sequence, not as standalone tactics. More on this in a future post specifically on tradeshow strategy.

Direct outreach and sales engagement is the channel where the buying committee question becomes most acute. Sales reps need to know what each contact has engaged with, what channel they came from, and where they are in their evaluation. Without that context, outreach feels generic and the relationship starts from zero even when the prospect has already consumed significant content.

Building Coordination Across Channels

The tactical question is how to actually connect these channels so they function as a system rather than a collection of independent programs.

Start with your CRM and marketing automation platform as the connective tissue. Every meaningful digital interaction — content downloads, email opens and clicks, webinar registrations, website page visits, form fills — should be captured in a system that gives both marketing and sales visibility into what a contact or account has engaged with. HubSpot, Marketo, and Salesforce Marketing Cloud are the most common platforms in this space. If your CRM and marketing automation aren't talking to each other, channel coordination is almost impossible to achieve.

Build content for the full buying committee, not just one persona. Map your content assets to the specific questions each stakeholder is asking at each stage of the buying process. Technical application notes and scientific webinars for the research and evaluation stakeholders. ROI frameworks, vendor evaluation guides, and compliance documentation for procurement and finance. Executive-level thought leadership for C-suite contacts. When a buying committee member arrives at your website or LinkedIn page, they should quickly find content that speaks to their specific context.

Use account-level engagement as your coordination signal. In a buying committee sale, individual lead scores can be misleading. What matters is whether the account as a whole is showing increased engagement across multiple contacts and channels. This is the logic behind account-based marketing: rather than tracking individual leads in isolation, you track account-level activity and use that signal to coordinate timing and messaging across channels. When multiple stakeholders at the same account are engaging simultaneously, that's a signal worth acting on.

Make your brand voice consistent across every channel. This sounds obvious and is surprisingly hard to execute. The tone and perspective in your LinkedIn posts should match the voice in your email nurture sequences, which should match what a sales rep says in an introductory call. When these feel misaligned, buyers notice, and it creates a subtle but real trust erosion. Messaging architecture (which we'll cover in a dedicated post on positioning) provides the foundation for this consistency.

The Measurement Challenge

Omnichannel strategy introduces a measurement complexity that simpler, single-channel programs don't face: when a deal closes after a buyer has touched six different channels over eight months, which channel gets credit? The honest answer is that no attribution model handles this perfectly. Last-click attribution, which is still the default in many organizations, dramatically overstates the role of the final touchpoint and undercounts everything that built awareness and consideration earlier in the cycle. Realistically, there’s no one marketing tactic or channel that is going to convert a complex life science sale on its own. It’s always the sales representative and science/technical support that are 100% responsible for making these complex sales. Marketing is a critical lever to build brand awareness and equity; soften the market so it’s prepared to hear how the product or service will solve their problems; and deliver market and customer insights that fuel the next innovation.

At the same time, we must be able to evaluate our multi-channel campaigns and understand whether we are reaching the appropriate target audience with the correct messaging and influencing the final decision. Multi-touch attribution is better in theory but requires clean data across all channels and a level of technical integration that some marketing teams haven't achieved. The practical approach is to use attribution models directionally rather than definitively, supplement them with direct conversation (asking buyers in sales calls and onboarding surveys how they found you and what influenced their decision), and focus reporting on pipeline contribution and revenue influence rather than trying to achieve perfect attribution precision.

What you're ultimately trying to measure is whether the coordinated system is working: are target accounts progressing through the buying cycle? Are multiple stakeholders within key accounts engaging? Is the handoff from marketing to sales happening with enough context to make sales conversations more productive?

The Real Goal

Omnichannel strategy is sometimes presented as a technology problem, a question of which platforms to integrate and which tools to deploy. Technology enables it, but the underlying goal is simpler and more human than any platform. The goal is to make every buyer feel like your company already understands them when they finally raise their hand. That the sales rep who calls knows what they've read. That the proposal reflects the specific concerns they've expressed. That the brand they've been encountering across channels for the past several months feels like a coherent, credible, trustworthy partner for a high-stakes decision.

In life sciences, where the buying cycle is long, the buying committee is complex, and trust is the deciding factor in most competitive situations, that feeling of coherence is worth more than any individual channel can deliver on its own. That's what an omnichannel strategy actually build s.

I work with life sciences companies on digital marketing strategy, from SEO and content to demand generation, positioning and messaging, omnichannel campaigns, product launches, voice of customer, and more. If this resonated, or if you have a different perspective, I'd genuinely like to hear from you.

Demand Generation in a Cookieless World: Intent Signals That Work

Fri, 27 Mar 2026 18:42:52 GMT

Demand Generation in a Cookieless World: Intent Signals That Actually Work

If you've been in B2B marketing for more than a few years, you've lived through at least one version of this conversation: the tools we've relied on are changing, the old playbook is breaking down, and we need to figure out what comes next. The death of the third-party cookie is that conversation's current chapter. And while it's been a slow-moving story (Google has delayed the full removal of third-party cookies in Chrome more times than most of us can count), the direction of travel is clear. The targeting infrastructure that B2B demand generation has leaned on heavily for the past decade is eroding, and the marketers who adapt early will have a real advantage over those who wait for the change to force their hand. The good news: the alternatives aren't just adequate. In many cases, they're better.

What We're Actually Losing

To understand what to replace, it helps to be specific about what third-party cookies actually did for demand generation. They enabled cross-site tracking, following a user from your website to other websites and building a behavioral profile over time. That profile powered retargeting campaigns, lookalike audience modeling, and the kind of frequency-capped, multi-touch display advertising that kept your brand in front of prospects who had visited your site but hadn't converted. For life sciences companies with long sales cycles and diffuse buying committees, that persistence mattered. A scientist who visited your product page in January and then saw a relevant ad in March was being nudged along a journey that third-party cookies made possible. Without them, that specific mechanism breaks. But what it leaves behind is a reason to build something more durable.

First-Party Data: The Foundation You Should Have Been Building Anyway

The most important shift in cookieless demand generation is the move from renting an audience to owning one. First-party data, meaning information your prospects and customers give you directly through their interactions with your owned channels, is both more valuable and more durable than anything you could buy or borrow through third-party tracking. In practice, building first-party data for a life sciences company means creating genuine reasons for your audience to identify themselves to you. Gated content that's worth gating: original research, technical white papers, protocol guides, benchmark reports. Not the "download our brochure" variety that nobody trades their email address for anymore. Webinars and virtual events that attract real practitioners. Newsletter subscriptions that deliver actual value. Demo requests and product trials that signal high intent.

The quality of what you're offering in exchange for contact information determines the quality of the audience you build. If you're generating a list of email addresses attached to people who downloaded a generic industry overview, you have a weak asset. If you're generating a list of scientists and lab managers who consumed a detailed technical guide on automating lab workflows, you have something genuinely useful. The investment required to build that kind of first-party asset is higher. The returns are proportionally better.

Intent Signals: Reading the Room Without Cookies

Beyond first-party data, the cookieless world has accelerated the maturation of intent data as a demand generation tool, and this is where things get interesting.

Behavioral signals on your own properties are the clearest intent indicators you have. Someone who visits your product page, reads three blog posts, downloads a technical guide, and then visits your pricing page is telling you something important without saying a word. Marketing automation platforms like HubSpot, Marketo, and Pardot have always been able to track this within your environment, and this capability is unaffected by the discontinuation of cookies. If you're not using progressive lead scoring based on on-site behavior, that's a high-priority gap to close.

Third-party intent data platforms like Bombora, TechTarget Priority Engine, and G2 Buyer Intent aggregate signals from across the web: content consumption patterns, review site activity, category research. These platforms use their own first-party data, collected with consent on their own properties, to build intent signals that are not dependent on third-party cookies. For life sciences companies targeting a defined set of accounts, layering intent data onto your ABM programs can dramatically improve prioritization, letting you focus sales and marketing energy on the accounts that are actually in a buying motion right now.

Social and community signals are harder to track but increasingly important. A significant portion of B2B buying research happens in places that are essentially invisible to traditional analytics: private Slack communities, LinkedIn DMs, industry forums, and conference conversations. You can't measure this directly, but you can influence it. Active participation in relevant communities, a strong LinkedIn presence, and a reputation for producing content that practitioners share with each other all build influence in these channels. When a scientist asks their peer network "who do you use for lab automation," you want your name to come up.

Search intent data, available through tools like SEMrush, Ahrefs, and Google Search Console, tells you what your target audience is actively searching for, which is a proxy for what they're thinking about. Mapping keyword intent to your content and paid search strategy ensures you're present at the moments when intent is highest and most legible.

ABM as the Organizing Framework

In a world where broad-based retargeting is harder, Account-Based Marketing becomes a more attractive organizing framework for demand generation. Rather than casting a wide net and hoping the algorithm finds the right people, ABM starts with a defined list of target accounts and orchestrates marketing activity specifically around those accounts.

For life sciences companies, where the total addressable market is often well-defined, deal sizes are meaningful, and sales cycles are long, ABM is a natural fit regardless of the cookie situation. But the cookieless transition makes it more compelling still, because the precision of ABM reduces the dependence on the broad behavioral tracking that third-party cookies enabled.

A well-executed ABM program in this environment combines intent data to prioritize accounts, first-party content assets to attract and engage them, LinkedIn targeting to reach specific personas within those accounts, and tight sales and marketing alignment to ensure that when an account raises its hand, someone is ready to respond quickly.

It's not a simple motion to run. But for complex B2B sales in life sciences, it's the right one.

What This Means for Your Measurement Approach

One underappreciated consequence of the cookieless shift is that it breaks some of the attribution models demand generation teams have relied on. Multi-touch attribution that tracked a prospect's journey across multiple sites and sessions becomes harder to reconstruct without third-party cookies. The response isn't to abandon measurement. It's to diversify it. Alongside whatever digital attribution your tools can still support, invest in direct conversation with your customers and prospects about how they found you and what influenced their decision. Ask in sales calls. Include it in onboarding surveys. Run periodic voice-of-customer research. The qualitative signal you get from simply asking people is often more accurate than the algorithms that were never as reliable as they looked.

Pipeline contribution, account engagement scores, and revenue influence are also more durable metrics than last-click or multi-touch attribution models that depend on complete tracking data. Orient your reporting around what you can measure reliably, and be honest about the limits of what you can't.

The Underlying Point

The cookieless transition is genuinely disruptive to some of the tactics demand generation has relied on. But the fundamentals it pushes you toward, including owned audience, genuine content value, intent-based prioritization, and account focus, are better marketing practices than what they're replacing.

The brands that treat this as a trigger to build something more durable will emerge stronger. The ones waiting for a technical workaround that recreates the old model are likely to be disappointed. Build the asset. Earn the attention. Read the intent. That's the playbook.

The Answer Engine Era: Getting Your Brand Cited by AI — and Why It Matters

Wed, 25 Mar 2026 20:02:27 GMT

The Answer Engine Era: Getting Your Brand Cited by AI — and Why It Matters Now

Something fundamental has shifted in how people find information. For most of the internet's history, the search box was a gateway — you typed a question, Google returned a list of doors, and you chose which one to open. That model isn't disappearing, but it's increasingly sharing the stage with something different.

Answer engines don't give you options. They give you answers. And if your brand isn't part of those answers, you're invisible in a way that doesn't even show up in your Google Search Console data. This is the world of Answer Engine Optimization (AEO) and its close cousin, Generative Engine Optimization (GEO.) If those terms are new to you, you're not alone. The terminology is still settling across the industry. But the underlying shift is real, it's accelerating, and for life sciences companies, understanding it now is a genuine competitive advantage.

What We're Actually Talking About

When someone opens ChatGPT and asks "what are the leading lab automation platforms for drug discovery," they're not getting ten blue links. They're getting a synthesized answer, drawn from the model's training data, sometimes supplemented by real-time web retrieval, which names specific companies, describes their capabilities, and frames the competitive landscape. The same is true of Perplexity, Gemini, Claude, and Microsoft's Copilot, a rapidly expanding set of platforms where buyers are increasingly starting their research. If your company isn't mentioned, you don't exist in that answer.

Perplexity operates with heavy real-time web retrieval; it's actively pulling from current sources and synthesizing them into a cited response. Google's Gemini is doing the same within the Google ecosystem. Microsoft's Copilot is weaving this into enterprise workflows. The common thread: a user asks a question, AI synthesizes an answer, and the brands that get named are the ones that have built the right kind of digital presence. AEO and GEO are about understanding what that "right kind of presence" looks like, and building it deliberately.

Why Life Sciences Companies Are Both Vulnerable and Well-Positioned

Here's the uncomfortable truth: many life sciences companies are poorly set up for the answer engine era. Websites that are heavy on product specs and light on educational content, minimal third-party validation, sparse publishing histories, and technical jargon that even an AI struggles to contextualize. These are characteristics that make a company easy to overlook when a model is synthesizing an answer about a category.

But there's an opportunity. The barriers to being cited are largely content and authority barriers, not technical ones. And life sciences companies that have real expertise, genuine innovation, and credible science behind their products have exactly what it takes to build the kind of presence that gets noticed. The playing field is more level than it looks if you know what you're building toward.

What Makes a Brand Citable

Think about how a well-read expert synthesizes an answer when someone asks them a question. They draw on sources they trust; sources that are authoritative, consistent, clearly written, and specific. AI models do something similar, and the factors that make a source trustworthy to a human map well to what makes content citable by AI.

Clarity and structure matter enormously. Content that answers questions directly with clear headings, logical organization, and specific rather than vague language is far more likely to be pulled into a synthesized answer than content that buries its point in marketing copy. If someone asks AI "how does a mass spectrometer work," and your website has a well-structured, clearly written page that explains exactly that, you're a candidate to be cited. If your page leads with "transforming the future of drug discovery" and takes three paragraphs to get to anything substantive, you're not.

Specificity beats generality. AI models are reasonably good at synthesizing general answers. They're much more likely to cite a source that offers something specific like a number, a mechanism, a named methodology, or a concrete outcome that adds to the answer rather than restating it. Original data, proprietary frameworks, and specific use cases are your most citable assets.

Consistent topical authority signals matter. Being cited isn't just about having one good page. Models learn to associate sources with topics over time, through the accumulation of relevant, high-quality content. A company that has published consistently on a topic builds a form of topical authority that makes it a go-to reference when that topic comes up in a query.

Third-party validation amplifies everything. Being mentioned, quoted, or cited by other credible sources such as industry publications, conference

proceedings, peer-reviewed content, and reputable blogs tells AI models that your brand is recognized by the broader community of knowledge on a topic. This is essentially the AEO equivalent of link building in traditional SEO, and it carries real weight.

Practical Steps to Start Building for AEO

You don't need to overhaul your entire content strategy overnight. A few focused moves will start building your AEO presence meaningfully.

Audit your existing content for answerability. Go through your key pages and ask honestly: if someone asked AI the question this page is trying to answer, would this content give the model something useful to work with? Look for pages that are vague, jargon-heavy, or structured around marketing messaging rather than genuine education. Those are your highest-priority rewrites.

Develop an FAQ architecture. One of the most reliable AEO tactics is building out robust FAQ content; content that's genuine, substantive, and answers the questions your buyers are actually asking. " How would DIA acquisition with AI-assisted spectral matching change peptide identification rates and quantitative reproducibility in a high-throughput Orbitrap proteomics workflow?" is the kind of question a serious buyer might put to an AI. If you have a thoughtful, specific answer on your site, you're a step ahead.

Pursue earned mentions deliberately. Identify the publications, platforms, and voices in your space that AI models are likely to draw from, and develop a strategy for getting mentioned there. Guest articles, contributed content, interview placements, and active participation in industry conversations all build the third-party citation trail that supports AEO authority.

Implement structured data. Schema markup (the technical layer that helps search engines and AI systems understand what your content is about) is more important than ever. Organization schema, FAQ schema, and article schema in particular help models correctly categorize and retrieve your content.

Create content that AI queries are likely to surface. Think about the questions your buyers are putting to AI tools right now. Map those questions to content on your site or create that content if it doesn't exist.

The Bigger Picture

AEO and GEO are not replacements for SEO. They're an expansion of the playing field. The fundamentals (clear content, genuine expertise, credible authority) are consistent across both. What changes is the format of the competition and the nature of the reward. In traditional SEO, winning means a high-ranking blue link. In the answer engine era, winning means being part of the answer itself. For life sciences companies with real science, real expertise, and real results to talk about, that's an opportunity that needs to be taken seriously.

The brands that start building now will have a meaningful head start. The category is still early enough that doing the basics well puts you ahead of the majority of your competitors. That window won't stay open forever.

I work with life sciences companies on digital marketing strategy -- from SEO/AEO/GEO , content marketing, demand generation, positioning and messaging, omnichannel campaigns, product launches, voice of customer, and more. If this resonated — or you have a different take — I'd genuinely like to hear from you.

Beyond Keywords: How Google's AI Overviews Are Rewriting the Rules of Organic Search

Tue, 24 Mar 2026 19:20:44 GMT

For the better part of two decades, the rules of SEO were relatively stable. Yes, Google's algorithm evolved constantly, from Panda to Penguin to BERT, but the fundamental game remained the same. Research keywords, create content, build authority, earn rankings, get clicks. Rinse and repeat.

That game hasn't ended. But it's changed more in the last eighteen months than it did in the previous ten years combined. And if you're still playing by the old rules, you're likely wondering why your organic traffic numbers look different than they used to.

The culprit, or the catalyst, depending on how you look at it is AI Overviews.

What AI Overviews Actually Do (And Why It Matters)

If you've searched Google recently, you've seen them: that block of AI-generated text that appears above the organic results, synthesizing an answer before you've clicked a single link. Google calls them AI Overviews. The SEO community has a lot of other names for them, some not suitable for professional publishing.

The core tension is straightforward. Google built its business on sending people to websites. AI Overviews, at their most extreme, answer the question so completely that there's no reason to click through at all. This phenomenon — getting an answer without visiting a source — is what researchers call "zero-click search," and it's accelerating.

Early data suggests that for informational queries, AI Overviews can reduce organic click-through rates significantly. Some studies have put that figure at 20–30% for affected query types, though the numbers vary by industry and search intent. For life sciences companies that have invested heavily in educational content — explainer pages, FAQs, how-it-works guides — this is not a theoretical concern. It's a traffic reality that's already showing up in Google Search Console.

The Queries That Are Most Affected

Not every search is equally impacted, and understanding where AI Overviews appear — and where they don't — is the first step to adapting your strategy. AI Overviews tend to dominate informational queries: "how does lab automation work," "what is a LIMS system," "difference between flow cytometry and mass cytometry." These are the educational, top-of-funnel questions that life sciences companies have been optimizing for years.

They appear far less frequently on commercial and transactional queries; searches that signal buying intent. "Lab automation vendors," "best LIMS for biotech," "request a demo", etc. are still, largely, territory where traditional organic listings and paid results hold the real estate. The practical implication: your middle-of-funnel and bottom-of-funnel content (comparison pages, use case content, solution pages) may actually be more valuable now than your purely educational content. The informational stuff will increasingly get absorbed into AI Overviews. The "help me decide" and "I'm ready to explore options" content is where organic clicks are more likely to survive.

What "Ranking" Even Means Now

Here's where things get philosophically interesting, and where I think a lot of marketers are still catching up.

Ranking used to mean appearing in positions one through ten on a results page. The goal was a blue link, a meta description, and a click. That mental model is increasingly incomplete.

There are now effectively two valuable positions in a Google search result:

Being cited within an AI Overview. Google pulls sources for its AI-generated answers, and those sources are often linked. Appearing as a cited source in an AI Overview can actually drive meaningful traffic — arguably more qualified traffic, since the user has already had their question partially answered and is clicking through for more depth or credibility.
Ranking below the AI Overview for queries where users still scroll. For complex, high-stakes decisions, which describe most B2B life sciences purchases, users often distrust a synthesized answer and want to read the source material. A strong position three or four below an AI Overview can still convert well if your snippet is compelling.

What's less valuable than it used to be: ranking for purely informational queries where a thorough AI Overview already satisfies the search intent completely. Traffic from those positions is declining, and in many cases no amount of optimization will recover it.

So What Should You Actually Do?

Here's what's working:

Shift your content investment toward specificity and depth. AI Overviews are reasonably good at synthesizing general answers. They're much weaker at capturing nuanced, experience-based, or highly specific content. A blog post titled "How lab automation affects your GMP compliance workflows" will hold its value far longer than one titled "What is lab automation." The more your content reflects genuine expertise and specific use cases, the less substitutable it is.

Build for citation, not just for ranking. Google's AI Overviews cite sources that demonstrate clear authority on a topic. This means structured, well-organized content with strong E-E-A-T signals -- Experience, Expertise, Authoritativeness, Trust. It means having credible authors, proper schema markup, clean site architecture, and original data or perspective that makes you citable rather than paraphraseable. We'll go deeper on E-E-A-T in a future post specifically on this topic.

Rethink your keyword strategy around intent tiers. Audit your existing keyword targets and honestly categorize them: informational (at risk), commercial (more protected), transactional (largely protected). Rebalance your content calendar accordingly. If 80% of your planned content is informational, you have concentration risk.

Double down on conversion optimization for the traffic you do get. If overall organic volume is declining, the math only works if your conversion rate improves. This means better CTAs, stronger landing page experiences, more compelling lead magnets, and tighter alignment between what your content promises and what happens when someone clicks through. Fewer visitors who convert at a higher rate can outperform more visitors who bounce.

Use Google Search Console to find your specific exposure. Every site is different. Pull your top informational queries and check whether AI Overviews are appearing for them. Look at your click-through rate trends over the past twelve months. The data will tell you exactly where the impact is landing in your specific situation — which is always more useful than industry averages.

The Bigger Strategic Point

There's a temptation to treat AI Overviews as a problem to be solved, a new obstacle to route around. What AI Overviews actually represent is Google making a judgment about what searchers want: faster, more direct answers to general questions. That's not going away. The companies that will win organic search over the next five years are the ones that stop competing on who can produce the most comprehensive answer to a generic question, and start building genuine authority through original research, deep expertise, specific use cases, and strong points of view

In life sciences, that advantage is more available than in almost any other sector. The science is complex, the buying decisions are high-stakes, and the questions that serious buyers are asking can't be fully answered by a paragraph of AI-generated text. That's your opening. The marketers who figure this out early will look very smart in two or three years. The ones still optimizing keyword density are going to have a rough time.

I work with life sciences companies on digital marketing strategy, from SEO and content to demand generation, positioning and messaging, omnichannel campaigns, product launches, voice of customer, and more . If this resonated — or if you disagree with any of it — I'd genuinely like to hear from you.